On May 3, 2022 Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol"), reported that it will publish the company’s results for the first quarter of 2022 on Thursday, May 12, 2022 (Press release, Isofol Medical, MAY 3, 2022, View Source [SID1234613352]). On the same day, Isofol invites investors, analysts, and media to an audiocast with a subsequent question and answer session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In conjunction with the publication of the interim report for the first quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on May 12, 2022 at 11:00 a.m. CEST. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.